Coherus Oncology, Inc. - Laporan Laba Rugi (TTM)

Coherus Oncology, Inc.
US ˙ NasdaqGM ˙ US19249H1032

Laporan Laba Rugi (TTM)

Laporan Laba Rugi Coherus Oncology, Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 489 476 443 395 364 327 304 276 239 211 183 182 211 257 227 179 175 267 272 272
Change (%) -2.75 -6.97 -10.85 -7.87 -10.19 -7.02 -9.05 -13.43 -11.72 -13.12 -0.78 16.02 21.88 -11.71 -21.32 -2.12 52.63 1.98 -0.02
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales -25 38 38 45 52 58 59 54 73 70 78 91 89 159 144 121 109 118 119 120
Change (%) -248.06 1.74 17.11 15.78 10.84 3.23 -9.12 35.45 -4.24 10.71 17.49 -2.78 79.39 -9.71 -16.05 -9.93 8.29 1.03 1.34
% of Revenue -5.20 7.92 8.66 11.37 14.29 17.64 19.58 19.57 30.61 33.21 42.31 50.11 41.99 61.81 63.21 67.44 62.07 44.03 43.62 44.21
Gross Operating Profit 515 438 404 350 312 269 244 222 166 141 106 91 122 98 84 58 66 149 153 152
Change (%) -14.87 -7.71 -13.50 -10.90 -13.70 -9.21 -9.04 -25.32 -15.02 -24.96 -14.19 34.90 -19.76 -14.95 -30.37 14.04 125.19 2.73 -1.06
% of Revenue 105.20 92.08 91.34 88.63 85.71 82.36 80.42 80.43 69.39 66.79 57.69 49.89 58.01 38.19 36.79 32.56 37.93 55.97 56.38 55.79
SG&A 137 139 143 149 157 170 179 190 195 198 195 193 192 186 170 148 139 150 147 145
Change (%) 1.18 2.91 4.40 5.31 7.85 5.52 6.10 2.58 1.83 -1.61 -1.30 -0.57 -3.14 -8.58 -12.51 -6.05 7.85 -2.40 -1.01
% of Revenue 28.09 29.23 32.33 37.86 43.28 51.97 58.98 68.81 81.53 94.05 106.50 105.95 90.79 72.16 74.72 83.08 79.75 56.35 53.93 53.40
R&D 192 143 310 342 357 363 246 229 221 199 151 129 112 106 100 101 93 93 89 95
Change (%) -25.73 117.10 10.26 4.46 1.72 -32.32 -6.66 -3.61 -9.83 -24.46 -14.57 -12.87 -5.58 -5.41 0.93 -7.49 -0.14 -4.36 6.39
% of Revenue 39.29 30.00 70.01 86.59 98.18 111.19 80.93 83.06 92.49 94.46 82.13 70.72 53.11 41.14 44.08 56.54 53.44 34.96 32.79 34.89
OpEx 304 320 491 536 566 590 484 473 489 468 423 413 392 450 413 370 342 361 355 361
Change (%) 5.02 53.79 9.09 5.64 4.26 -17.98 -2.24 3.33 -4.35 -9.50 -2.58 -4.90 14.80 -8.23 -10.48 -7.71 5.80 -1.79 1.64
% of Revenue 62.18 67.15 111.00 135.83 155.74 180.80 159.49 171.44 204.63 221.72 230.94 226.77 185.89 175.10 182.00 207.07 195.26 135.35 130.35 132.50
Operating Income 185 156 -49 -141 -203 -264 -181 -197 -250 -257 -240 -231 -181 -193 -186 -191 -167 -94 -83 -88
Change (%) -15.52 -131.15 190.32 43.36 30.18 -31.54 9.21 26.80 2.70 -6.53 -3.94 -21.39 6.57 -3.60 2.73 -12.92 -43.36 -12.45 7.09
% of Revenue 37.82 32.85 -11.00 -35.83 -55.74 -80.80 -59.49 -71.44 -104.63 -121.72 -130.94 -126.77 -85.89 -75.10 -82.00 -107.07 -95.26 -35.35 -30.35 -32.50
Interest Expense -20 -21 -22 -23 -23 -23 -26 -27 -29 -32 -33 -37 -39 -41 -34 -28 -23 -27 -26 -24
Change (%) 5.95 5.75 1.51 0.51 0.53 14.46 3.17 6.52 12.44 2.29 10.12 7.46 3.14 -16.26 -17.32 -17.48 17.26 -3.56 -6.82
% of Revenue -4.08 -4.45 -5.06 -5.76 -6.28 -7.03 -8.66 -9.82 -12.08 -15.39 -18.12 -20.11 -18.62 -15.76 -14.95 -15.71 -13.24 -10.17 -9.62 -8.97
Net Income 162 132 -76 -165 -232 -287 -210 -230 -279 -292 -271 -264 -217 -238 -59 -29 -0 29 -131 180
Change (%) -18.25 -157.68 116.59 40.23 23.93 -26.77 9.63 20.88 4.72 -6.98 -2.68 -17.80 9.57 -75.08 -50.51 -98.47 -6,434.89 -559.32 -237.28
% of Revenue 33.06 27.79 -17.23 -41.86 -63.71 -87.92 -69.24 -83.47 -116.54 -138.24 -148.01 -145.18 -102.86 -92.48 -26.10 -16.42 -0.26 10.68 -48.09 66.03

Source: Capital IQ

Other Listings
DE:8C5 € 1.11
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista